PDS Biotech Registers 13.3M Shares for Resale, Turning Its $5.76M Financing Overhang Tradable
PDSB sits 50% above its 52-week low of $0.507 on light trading volume (0.3× avg).
Summary
PDS Biotech registered 13.3 million shares for resale by YA II PN, making the overhang from its June $5.76M financing tradable. The convertible note's discount-to-market terms pose dilution risk if the company stumbles.
Key Events · Financing and Capital Events · PDSB
-
13.3M Share Resale Registration
The S-3 registers 2,158,274 warrant shares (exercise price $1.1824) and 11,157,549 shares issuable upon conversion of a $6M promissory note held by YA II PN, LTD.
-
Convertible Note Terms Pose Dilution Risk
Upon default, the note converts at 95% of the lowest 5-day VWAP or 92% of the prior close, potentially at a steep discount to the current $0.76 price, amplifying dilution.
-
Follow-Through on June 2026 Financing
This registration fulfills the Registration Rights Agreement from the $5.76M financing that closed June 15, 2026, making the overhang tradable for the first time.
-
Capital Raise Context
The filing comes amid a series of financings, including a $50M ATM program and a pending shareholder vote to double authorized shares to 300 million, highlighting ongoing cash needs.
Analysis · PDSB · Life Sciences
An S-3 filed by PDS Biotech registers 13.3 million shares for resale by YA II PN, LTD., the investor behind its June 2026 $5.76 million financing. The shares underlie a $6 million convertible note and a warrant struck at $1.18. While the financing was previously disclosed, this registration makes the overhang immediately tradable. At today's $0.76 stock price, the note's conversion terms—95% of the lowest VWAP over five days or 92% of the prior day's close—could result in deeply discounted issuances if the company defaults, creating significant dilution risk. The filing follows a series of capital raises and a pending shareholder vote to double authorized shares, underscoring the company's urgent need for cash to fund its clinical programs.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 29.5% of the 2875 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.2M. The 52-week trading range was $0.51 to $1.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.